Squarepoint
ZBIO

Squarepoint’s Zenas BioPharma ZBIO Stock Holding History

Squarepoint’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Buy
125,185
+82,311
+192% +$1.64M ﹤0.01% 1965
2026
Q1 		$838K Buy
42,874
+27,333
+176% +$614K ﹤0.01% 2929
2025
Q4 		$564K Buy
+15,541
New +$511K ﹤0.01% 3107
2024
Q4 		– Sell
-32,299
Closed -$546K – 5588
2024
Q3 		$546K Buy
+32,299
New +$581K ﹤0.01% 3025

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Squarepoint's ZBIO Position: Q2 2026 in Review

Squarepoint increased its Zenas BioPharma (ZBIO) stake by 192% in Q2 2026, buying an estimated $1.64M and bringing the position to 125,185 shares worth $3.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

Squarepoint first reported a position in ZBIO in Q3 2024 and has held it in 4 quarters since. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Squarepoint held 125,185 shares of Zenas BioPharma worth $3.18M as of Q2 2026.
  • Squarepoint bought 82,311 Zenas BioPharma shares in Q2 2026, an estimated $1.64M.
  • Zenas BioPharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #1965 holding.
  • Squarepoint first reported a position in Zenas BioPharma in Q3 2024 and has held it in 4 quarters since.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.